<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02059096</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0179</org_study_id>
    <secondary_id>2013-A01422-43</secondary_id>
    <nct_id>NCT02059096</nct_id>
  </id_info>
  <brief_title>Analgesic Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) for Central Neuropathic Pain in Multiple Sclerosis</brief_title>
  <acronym>STIMASEP</acronym>
  <official_title>Analgesic Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) for Central Neuropathic Pain in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the effect of repetitive Transcranial Magnetic Stimulation&#xD;
      (rTMS) in the resolution of chronic pain. Participants will be patients with Multiple&#xD;
      Sclerosis suffering from chronic pain of neurological origin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On the one hand, Multiple Sclerosis (MS) is the most frequent chronic disease generating&#xD;
      neurological disability in young adults. Among the many types of disabilities associated with&#xD;
      MS, chronic pain is very frequent, especially neuropathic pain. This type of pain is often&#xD;
      treatment resistant. Moreover, abnormal intra-cortical excitability has been described in MS&#xD;
      patients.&#xD;
&#xD;
      On the other hand, repetitive Transcranial Magnetic Stimulation (rTMS) has shown an analgesic&#xD;
      effect in various chronic pain conditions (fibromyalgia, post-stroke, peripheral neuropathic&#xD;
      pain). Three groups have shown that analgesia was correlated to defective intra-cortical&#xD;
      excitability restoration.&#xD;
&#xD;
      The goal of this study is to compare the analgesic effects of two types of primary Motor&#xD;
      cortex (M1) rTMS, namely 10Hz and prolonged continuous Theta-Burst Stimulation (pcTBS), with&#xD;
      sham stimulation.&#xD;
&#xD;
      Patients will benefit from 1 daily session per day for 5 consecutive days and from a total&#xD;
      follow up of 4 weeks. Pain will be assessed each day and several other signs and symptoms&#xD;
      will be repeatedly assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2014</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in &quot;average pain&quot; score on the brief pain inventory</measure>
    <time_frame>at day 8</time_frame>
    <description>Variation of the &quot;Average pain&quot; score on the Brief Pain Inventory between before treatment (on a 7 days period) and day 8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change from baseline in &quot;average pain&quot; score on the brief pain inventory</measure>
    <time_frame>at weekk 3 and 4</time_frame>
    <description>Variation of the average pain at several time-points during the 4 weeks follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Location of MRI abnormalities</measure>
    <time_frame>at week 3 and 4</time_frame>
    <description>Correlation between pain and pain decrease with MRI abnormalities in several regions of interest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-cortical excitability evaluated by motor threshold, MEP amplitude, SICI and ICF</measure>
    <time_frame>at week 3 and 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>at day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in specific questionnaires</measure>
    <time_frame>at day 8, week 3 and 4</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Multiple Sclerosis With Central Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>Repetitive transcranial magnetic stimulation (rTMS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The goal of this study is to compare the analgesic effects of two types of primary Motor cortex (M1) rTMS, namely 10Hz and prolonged continuous Theta-Burst Stimulation (pcTBS), with sham stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Theta-Burst Stimulation (pcTBS)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The goal of this study is to compare the analgesic effects of two types of primary Motor cortex (M1) rTMS, namely 10Hz and prolonged continuous Theta-Burst Stimulation (pcTBS), with sham stimulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>repetitive Transcranial Magnetic Stimulation (rTMS)placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The goal of this study is to compare the analgesic effects of two types of primary Motor cortex (M1) rTMS, namely 10Hz and prolonged continuous Theta-Burst Stimulation (pcTBS), with sham stimulation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Repetitive Transcranial Magnetic Stimulation (rTMS)</intervention_name>
    <arm_group_label>Repetitive transcranial magnetic stimulation (rTMS)</arm_group_label>
    <arm_group_label>Theta-Burst Stimulation (pcTBS)</arm_group_label>
    <arm_group_label>repetitive Transcranial Magnetic Stimulation (rTMS)placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  relapsing-remitting Multiple Sclerosis&#xD;
&#xD;
          -  18 to 60 years&#xD;
&#xD;
          -  central neuropathic pain with a DN4 score of 4 or more out of 10&#xD;
&#xD;
          -  average pain of at least 4/10&#xD;
&#xD;
          -  presence of pain at least 4 days per week&#xD;
&#xD;
          -  presence of pain for at least 3 months&#xD;
&#xD;
          -  stable analgesic treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  relapse during the previous 30 days&#xD;
&#xD;
          -  contraindication for rTMS&#xD;
&#xD;
          -  peripheral neuropathic pain&#xD;
&#xD;
          -  severe depression&#xD;
&#xD;
          -  epilepsia&#xD;
&#xD;
          -  resting motor threshold above 75%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier MOISSET</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lise LACLAUTRE</last_name>
    <phone>04 73 75 4963</phone>
    <email>promo_interne_drci@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Ambroise Paré</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier BOUHASSIRA</last_name>
    </contact>
    <investigator>
      <last_name>Didier BOUHASSIRA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lise Laclautre</last_name>
      <phone>04 73 75 4963</phone>
      <email>promo_interne_drci@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre Clavelou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pascal Lefaucheur</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Pascal Lefaucheur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 6, 2014</study_first_submitted>
  <study_first_submitted_qc>February 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2014</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Repetitive transcranial magnetic stimulation (rTMS)</keyword>
  <keyword>Chronic neuropathic pain</keyword>
  <keyword>Cortical excitability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

